Agomelatine-induced thrombocytopenic purpura, a possible new adverse effect

Therapie. 2017 Jun;72(3):401-402. doi: 10.1016/j.therap.2016.09.006. Epub 2016 Nov 11.

Authors

Delphine Bourneau-Martin¹, Renaud Blanchard², Anne-Bérangère Beucher³, Guillaume Drablier⁴, Laurence Lagarce⁴, Pascale Lainé-Cessac⁴

Affiliations

¹ Pharmacovigilance Centre, Pharmacology-Toxicology Department, Angers University hospital, 4, rue Larrey, 49933 Angers, France. Electronic address: DeBourneau@chu-angers.fr.
² 49100 Angers, France.
³ Internal Medicine Department, Angers University Hospital, 49933 Angers, France.
⁴ Pharmacovigilance Centre, Pharmacology-Toxicology Department, Angers University hospital, 4, rue Larrey, 49933 Angers, France.

PMID: 27939071
DOI: 10.1016/j.therap.2016.09.006

No abstract available

Keywords: Agomelatine; Agomélatine; Purpura thrombopénique; Thrombocytopenic purpura.

Publication types

Case Reports
Letter

MeSH terms

Acetamides / adverse effects*
Female
Humans
Hypnotics and Sedatives / adverse effects*
Middle Aged
Purpura, Thrombocytopenic / chemically induced*

Substances

Acetamides
Hypnotics and Sedatives
agomelatine